P256 Bowel contrast-enhanced ultrasound perfusion imaging in the evaluation of Crohn's disease patients
L. Laterza*1, M. E. Ainora1, M. Garcovich1, A. Poscia2, A. Lupascu3, L. Riccardi1, F. Scaldaferri1, A. Armuzzi4, A. Gasbarrini1, G. L. Rapaccini4, M. Pompili1, M. A. Zocco1
1Fondazione Policlinico A. Gemelli IRCCS, Internal Medicine and Gastroenterology, Rome, Italy, 2Catholic University, Institute of Public Health, Rome, Italy, 3Fondazione Policlinico A. Gemelli IRCCS, Angiology, Rome, Italy, 4Fondazione Policlinico A. Gemelli IRCCS, Presidio Columbus, Rome, Italy
Evaluation of inflammation in Crohn’s disease (CD) is crucial for treatment planning and monitoring. The use of contrast enhanced ultrasound (CEUS) could be important in the diagnosis and follow-up since it is a non-invasive and easily repeatable method. We aimed to prospectively evaluate the role of CEUS in CD.
In total, 54 patients with active ileal CD starting infliximab were enrolled. Clinical assessment, laboratory tests and CEUS were performed at baseline (T0) and after 2 (T1), 6 (T2) and 12 weeks (T3) of treatment to assess variations in peak intensity (PI), area under the curve (AUC), slope of wash in (Pw), time to peak (TP), mean transit time (MTT). Deep remission was defined as SES-CD = 0 or decreased of at least 1 unit plus CDAI < 70 at T3. Clinical relapse was assessed up to 3 months.
70% of patients achieved deep remission (responders). The delta between T0 and T1 was significantly different in responders and non-responders in PI, AUC, Pw, and MTT. Ninety-five per cent of patients showed a reduction in PI, 100% in AUC, 84% in Pw, 26% in TP and 50% in MTT. There was a good correlation between ratio in CEUS parameters between T1-T0 and T2-T0 and T3-T0. The eight patients who relapsed showed lower mean percentage reduction in delta PI between T1 and T0 and between T2 and T0 compared with patients in remission (−8.4 vs. −20.76,
CEUS could be useful as reliable predictor of deep remission and clinical relapse in patients with CD treated with infliximab.